Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.

GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.

Cardiovascular medicine is undergoing transformative change as gene therapy emerges as a promising approach to address heart failure and cardiac ...

The FDA AMT designation verifies NanoMosaic platform's ability to enhance efficiency, product quality, and scalability across AAV gene therapy manufacturing.

Ace Therapeutics announces its preclinical ophthalmic drug development services to help expedite the discovery of ...

Key trends include strategic CDMO partnerships and a shift to in vivo administration, enhancing accessibility and innovation ...

Sanofi’s participation will support the progression of Sensorion’s genetic medicine pipeline.

Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical ...

Join the ELRIG conference to hear from experts on cell and gene therapy. Discover advancements shaping the future of medicine.

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

NanoMosaic's technology is designed to support upstream and downstream process development, quality control, and release testing.

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, today announced the ...